David L. DeRemer, PharmD, BCOP, and Bently P. Doonan, MD, MS, share a perspective on ocular toxicities associated with MEK inhibition.
David L. DeRemer, PharmD, BCOP
Advertisement
Articles by David L. DeRemer, PharmD, BCOP
Advertisement
Latest Updated Articles
Evaluating Treatment Options and the Multidisciplinary Care of Ocular Toxicities of MEK InhibitorsPublished: April 1st 2023 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer
3
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
4
How Can Lower-Income Countries Maintain Representation in Clinical Trials?
5
